Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

Keyphrases

• Respiratory Syncytial Virus Infection 100%
• Cystic Fibrosis 100%
• Infections in children 100%
• Palivizumab 100%
• Placebo 36%
• Adverse Events 27%
• Respiratory Syncytial Virus 27%
• Two-year-olds 18%
• Bacterial Colonization 18%
• Respiratory Syncytial Virus Hospitalization 18%
• No Significant Difference 9%
• Hospitalization 9%
• Tolerability 9%
• Randomized Controlled Trial 9%
• Young children 9%
• Infant Patients 9%
• Between-group 9%
• Lung Inflammation 9%
• Inclusion Criteria 9%
• Risk of Bias 9%
• Selection Criteria 9%
• Cochrane 9%
• Placebo Groups 9%
• Search Methods 9%
• Intensive Care Unit Admission 9%
• Intensive Care 9%
• Serious Adverse Events 9%
• Extracted Data 9%
• Children at Risk 9%
• Health Support 9%
• Pseudomonas 9%
• Clinically Meaningful Difference 9%
• Putting 9%
• Hospitalization Rate 9%
• Genetic Disease 9%
• Change in Weight 9%
• Chronic Airways Disease 9%
• Respiratory Support 9%
• Acute Lung Infection 9%
• Weight-to-height Ratio 9%
• Synagis 9%

Medicine and Dentistry

• Respiratory Syncytial Virus Infection 100%
• Cystic Fibrosis 100%
• Palivizumab 100%
• Human Respiratory Syncytial Virus 41%
• Placebo 41%
• Adverse Event 33%
• Bacterial Colonization 16%
• Randomized Controlled Trial 8%
• Pneumonia 8%
• Toddlers 8%
• Pseudomonas 8%
• Intensive Care Unit 8%
• Intensive Care 8%
• Genetic Disorder 8%
• Group Trial 8%
• Lung Infection 8%
• Assisted Ventilation 8%
• Chronic Airway Disease 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Respiratory Syncytial Virus Infection 100%
• Cystic Fibrosis 100%
• Palivizumab 100%
• Placebo 41%
• Human Respiratory Syncytial Virus 41%
• Adverse Event 33%
• Tolerability 8%
• Randomized Controlled Trial 8%
• Pneumonia 8%
• Group Trial 8%
• Pseudomonas 8%
• Genetic Disorder 8%
• Respiratory Tract Disease 8%
• Lung Infection 8%